Taishi Hirai, MD
Interventional Cardiology · Columbia, MONPI 1932495165
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abiomed accounts for 61.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $56,497 and has fallen 99.4% since, to $364 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $440.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$92K
- Siemens Medical Solutions USA, Inc.$26K
- Asahi Intecc CO., LTD.$14K
- Asahi Intecc USA, Inc.$8K
- Boston Scientific$5K
- Abbott$2K
- plus $4K from 22 others
Across 21 payments — averaging $7629.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$76K
- Boehringer Ingelheim Pharma GmbH & Co.kg$55K
- Siemens Medical Solutions USA, Inc.$22K
- Astrazeneca UK Limited$7K
What the payments were for
- Consulting fees$23,15015%
- Speaking & faculty fees$76,57151%
- Travel & lodging$36,25724%
- Food & beverage$14,1519%
- Gifts$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 51 | $92,303 |
| Siemens Medical Solutions USA, Inc. | 33 | $25,594 |
| Asahi Intecc CO., LTD. | 23 | $13,968 |
| Asahi Intecc USA, Inc. | 15 | $7,983 |
| Boston Scientific | 104 | $5,150 |
| Abbott | 16 | $1,613 |
| Amgen | 31 | $903 |
| Biotronik Inc. | 6 | $438 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $337 |
| Johnson & Johnson | 4 | $288 |
| Medtronic(2 entities) | 10 | $249 |
| Shockwave Medical, Inc | 3 | $197 |
| Philips North America LLC | 4 | $187 |
| Livanova USA, Inc. | 3 | $186 |
| Cardiovascular Systems Inc. | 2 | $169 |
| Novartis | 7 | $115 |
| Biosense Webster, Inc. | 1 | $87 |
| Seigla Medical, Inc. | 1 | $87 |
| Teleflex LLC | 3 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
| Terumo Medical Corporation | 1 | $41 |
| Corindus Inc. | 1 | $26 |
| Altathera Pharmaceuticals LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Merck | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$91,394
- ASAHI PTCA Guide Wire$15,948
- ASAHI PTCA Guide Wire ASAHI Gladius Mongo 14$2,500
- PERIPHERAL VASCULAR$2,205
- Artis Q.zen floor$1,765
- HeartMate Touch$900
- CorPath Imaging System$885
- GENERAL - THERAPIES$721
- MINAMO and MINAMO 2.0$500
- AVVIGO Guidance System$351
- GENERAL VASCULAR ACCESS$302
- Diamondback Coronary$281
- STINGRAY$254
- CROSSBOSS$242
- Xience Alpine cornary stent system$188
- CorPath GRX$179
- COROFLOW$146
- Orsiro Mission$141
- XARELTO$120
- ReCross$113
How this compares
$150,149 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 37 | $40,907 |
| Repatha SureclickEvolocumab | 24 | $30,223 |
| EliquisApixaban | 13 | $23,512 |
| FarxigaDapagliflozin Propanediol | 18 | $19,829 |
| Praluent PenAlirocumab | 22 | $18,973 |
| Atorvastatin Calcium | 117 | $1,351 |
| Metoprolol Succinate | 78 | $886 |
| ClopidogrelClopidogrel Bisulfate | 95 | $874 |
| Losartan Potassium | 64 | $689 |
| Spironolactone | 57 | $426 |
| Amlodipine Besylate | 36 | $249 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 27 | $243 |
| Ezetimibe | 13 | $205 |
| Nitroglycerin | 17 | $193 |
| Lisinopril | 28 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $115 | $40,90737 claims |
| AstraZenecaFarxiga | $12 | $19,82918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Columbia
- Arun KumarColumbia$17K
- Michael BrownColumbia$17K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.